Column · Cost & Coverage
Compounded vs. Brand GLP-1, on a Family Budget
Brand-name Wegovy or a compounded vial at a third of the price? What the real difference is, and how to weigh it against a family's actual budget.
Evidence reviewed by Reed Ellsworth — a former pharmaceutical-industry analyst, not a treating clinician.
Two prices for what looks like the same thing
Open two telehealth tabs and you will see the same active ingredient quoted at wildly different prices: brand-name Wegovy or Zepbound at the pharmacy counter, and a compounded semaglutide or tirzepatide vial at a fraction of it. For a family doing the arithmetic, the gap is impossible to ignore. But it is not a coupon — the two are genuinely different products, and understanding how is the difference between a smart budget decision and a blind one.
What the trial data actually measured
Start with a fact that helps and complicates at once: the celebrated efficacy numbers belong to the *brand* molecules. When you read that semaglutide produced roughly 15% mean weight loss in STEP 11, or that tirzepatide reached near 20% in SURMOUNT-12, those trials studied the FDA-approved branded drugs at defined doses. Compounded versions use the same active ingredient, but they were not the specific products tested, and they are not FDA-approved. It is reasonable to expect a similar effect from the same molecule at the same dose — but "reasonable to expect" is doing real work in that sentence, and an honest budget accounts for it.
Why compounded exists, and why that matters
Compounded GLP-1 medicines expanded largely because the brand products spent long stretches on the FDA's drug-shortage list, and federal rules allow compounding pharmacies more latitude when a drug is in shortage3. That is the legitimate origin story. It also means the landscape is unstable: as shortages resolve, the rules that made large-scale compounding permissible can tighten, and a low price you are counting on may not be permanent. A compounded vial is not a knockoff in the back-alley sense — it is dispensed by a licensed pharmacy — but it is a product whose availability rides on a regulatory situation that changes.
Doing the honest math for your family
So how should a mother weigh it? First, price the *maintenance* dose, not the starting dose, because that is where you will live — the same logic that governs the true cost of a GLP-1 over time. Second, weigh the compounded discount against what you give up: FDA-approved manufacturing, and in many cases the ability to run the drug through insurance, which can make a "more expensive" brand cheaper than a "cheap" compounded vial once coverage applies. Third, favor a provider that is transparent about which product you are getting and at what dose. Our top-ranked pick, CoreAge Rx, competes on a flat, disclosed compounded price rather than a teaser — and you can compare it against brand-forward providers that lean on insurance navigation instead. There is no universally right answer here; there is only the one that survives your budget with your eyes open. This column is educational and is not medical or financial advice; confirm current pricing and product details directly with any provider and clinician.
Frequently asked questions
Is compounded semaglutide the same as Wegovy?
It uses the same active ingredient but is not the FDA-approved branded product and was not the specific drug studied in the major trials. It is dispensed by licensed compounding pharmacies, largely because the brand products spent time on the FDA shortage list.
Is brand-name always more expensive than compounded?
Not necessarily. Cash-pay brand pricing is high, but if your insurance covers a brand GLP-1, your out-of-pocket cost can end up lower than a compounded vial. Price both the maintenance dose and your coverage before deciding.
References
- Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
- U.S. Food and Drug Administration (2024). Compounding and Drug Shortages. FDA Human Drug Compounding. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-drug-shortages
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
The True Cost of GLP-1, Once the Dose Climbs
The price you sign up for is rarely the price you pay six months in. What a GLP-1 really costs a family once the dose reaches maintenance.
ReadGLP-1 and the Diet Culture We Grew Up With
The mothers starting GLP-1 today were raised on SlimFast and shame. What it means to treat weight as biology after a lifetime of blaming willpower.
ReadWhat to Tell Your OB Before You Start a GLP-1
Before your first injection, a conversation with your OB-GYN — on pregnancy timing, contraception, and the questions worth raising first.
ReadGLP-1 and the Mental Load of Feeding a Family
Mothers plan, shop for, and worry about everyone's meals but their own. What happens to that invisible labor when a medication quiets the food noise.
ReadPerimenopause, Appetite, and Where a GLP-1 Fits
The hunger and body changes of your forties are not a character flaw. On perimenopause, shifting body composition, and where a GLP-1 fits in.
Read